Add to ORKGThe outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic
We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 mo...
The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these p...
In the current COVID-19 pandemic, patients diagnosed with multiple sclerosis (MS) are considered to ...
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has ra...
Since COVID-19 has emerged as a word public health problem, attention has been focused on how immune...
Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have t...
Background: With the spread of COVID-19, treatment of diseases such as multiple sclerosis (MS) shoul...
Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particu...
BACKGROUND: In view of the emerging coronavirus pandemic, the demand for knowledge about the impact ...
ABSTRACT Purpose: The purpose of this article is to review the treatment changes that occurred for p...
Background The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) ma...
Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) pat...
Background: The SARS-CoV-2 pandemic impact on people with Multiple Sclerosis (pwMS) continues to wor...
Introduction: Covid-19 has been sweeping over the world for more than a year. People with Multiple S...
Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving disease-modif...
We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 mo...
The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these p...
In the current COVID-19 pandemic, patients diagnosed with multiple sclerosis (MS) are considered to ...
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has ra...
Since COVID-19 has emerged as a word public health problem, attention has been focused on how immune...
Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have t...
Background: With the spread of COVID-19, treatment of diseases such as multiple sclerosis (MS) shoul...
Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particu...
BACKGROUND: In view of the emerging coronavirus pandemic, the demand for knowledge about the impact ...
ABSTRACT Purpose: The purpose of this article is to review the treatment changes that occurred for p...
Background The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) ma...
Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) pat...
Background: The SARS-CoV-2 pandemic impact on people with Multiple Sclerosis (pwMS) continues to wor...
Introduction: Covid-19 has been sweeping over the world for more than a year. People with Multiple S...
Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving disease-modif...
We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 mo...
The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these p...
In the current COVID-19 pandemic, patients diagnosed with multiple sclerosis (MS) are considered to ...